Olympus launches new AI platform for endoscopy system
Olympus launches new AI platform for endoscopy system

Olympus has announced the launch of ENDO-AID, a platform powered by artificial intelligence (AI) that includes the endoscopy application ENDO-AID CADe (computer-aided detection) for the colon.

This new AI platform enables real-time display of automatically detected suspicious lesions and works in combination with Olympus’ recently introduced EVIS X1, its most advanced endoscopy system to date. 

By designing and delivering solutions for medical and surgical procedures, Olympus aims to improve the health and quality of life of patients by providing advanced medical technologies. Its latest endoscopy system, EVIS X1, was developed to improve image detection, characterisation, staging, and treatment. With the newly introduced endoscopy CAD (computer-aided detection/diagnosis) platform ENDO-AID, Olympus is now enhancing the capabilities of EVIS X1 through AI technology.

ENDO-AID CADe is an application for computer-aided detection powered by AI which runs on ENDO-AID. It uses an algorithm via a neural network developed and trained by Olympus. With this new application, the system’s machine learning can alert the endoscopist in real time when a suspected colonic lesion (such as a polyp, malignant neoplasm or adenoma) appears on the screen.

ENDO-AID CADe was developed toward the following improvements: 

  • Improved observational performance in adenoma detection: By providing visual support, ENDO-AID CADe aims to improve the observational performance of the endoscopist’s adenoma detection.
  • Support of the colonoscopy screening process: The system provides visual support during screening, allowing the endoscopist to focus on any abnormalities indicated by the software regardless of the experience level of the endoscopist.
  • Efficient endoscopy operation: Due to the simple and intuitive display of lesions, ENDO-AID CADe has the potential to make endoscopy easier and more efficient for the endoscopist by reducing the need for excessive eye movements.

Frank Drewalowski, head of endoscopic solutions division, Olympus, said: “At Olympus we are committed to innovation and driving our research and development with passion. Especially in AI, we recognise the power of elevating endoscopic imaging to uncharted levels. Considering ENDO-AID as a first step, we are planning additional AI-powered applications for image detection and characterisation – not only for colonoscopy.”

There is a positive impact of an increase in adenoma detection rate (ADR) on the prevention of colorectal cancer (CRC). Supporting the identification of lesions, ENDO-AID CADe is designed to increase ADR.

Takaharu Yamada, vice president, GI Endoscopy business leader, Endoscopic Solutions Division, said: “With the launch of ENDO-AID, we are not only providing endoscopists across the world with an additional innovative tool. We are also preparing for the future and following our vision of putting CRC in the history books.”  

Related: Start up raises Eur 143k to scale up smart inhaler technology